Laboratorios Farmaceuticos ROVI SA
MAD:ROVI

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Watchlist
Price: 61.7 EUR -0.08% Market Closed
Market Cap: 3.1B EUR
Have any thoughts about
Laboratorios Farmaceuticos ROVI SA?
Write Note

Operating Margin
Laboratorios Farmaceuticos ROVI SA

27.8%
Current
29%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27.8%
=
Operating Profit
281.7m
/
Revenue
1B

Operating Margin Across Competitors

Country ES
Market Cap 3.2B EUR
Operating Margin
28%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 749.1B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 348B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 150.1B USD
Operating Margin
22%
No Stocks Found

Laboratorios Farmaceuticos ROVI SA
Glance View

Market Cap
3.2B EUR
Industry
Pharmaceuticals
Economic Moat
Narrow

Laboratorios Farmacéuticos ROVI SA has carved a niche for itself in the pharmaceutical industry through its focus on researching, developing, manufacturing, and marketing a broad range of small molecule drugs and specialized products. Founded in Spain, ROVI has channeled its efforts towards creating innovative solutions in the healthcare sector, with heparin-based products emerging as a cornerstone of its portfolio. The company's operational model is built on vertical integration, allowing it to control the entire lifecycle of its offerings, from production to commercialization. This approach not only ensures quality and compliance with stringent regulatory standards but also enables ROVI to adapt nimbly to market demands and leverage its proprietary science to secure a competitive edge. The revenue streams of ROVI are diversified across its proprietary products, contract manufacturing services, and its portfolio of licensed products. A significant portion of revenue stems from its commitment to injectable drug products like Bemiparin, a low molecular weight heparin, which has found a foothold in various international markets. Moreover, ROVI capitalizes on partnerships and alliances with major pharmaceutical giants, augmenting its contract manufacturing capabilities and tapping into more extensive distribution networks. Not resting on its laurels, ROVI invests heavily in research and development to fortify its pipeline with innovative formulations, thus ensuring sustained growth and a resilient positioning in the global pharmaceutical landscape. This blend of strategic partnerships, internal innovation, and market-responsive production underscores ROVI's business model and revenue generation prowess.

ROVI Intrinsic Value
87.01 EUR
Undervaluation 29%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27.8%
=
Operating Profit
281.7m
/
Revenue
1B
What is the Operating Margin of Laboratorios Farmaceuticos ROVI SA?

Based on Laboratorios Farmaceuticos ROVI SA's most recent financial statements, the company has Operating Margin of 27.8%.